Brain tumors are among the most lethal and devastating cancers. Their study is limited by genetic heterogeneity and the incompleteness of available laboratory models. Three-dimensional organoid culture models offer innovative possibilities for the modeling of human disease. Here we establish a 3D in vitro model called a neoplastic cerebral organoid (neoCOR), in which we recapitulate brain tumorigenesis by introducing oncogenic mutations in cerebral organoids via transposon-and CRISPR-Cas9mediated mutagenesis. By screening clinically relevant mutations identified in cancer genome projects, we defined mutation combinations that result in glioblastoma-like and central nervous system primitive neuroectodermal tumor (CNS-PNET)-like neoplasms. We demonstrate that neoCORs are suitable for use in investigations of aspects of tumor biology such as invasiveness, and for evaluation of drug effects in the context of specific DNA aberrations. NeoCORs will provide a valuable complement to the current basic and preclinical models used to study brain tumor biology.
M alignant brain tumors are among the most devastating cancers, with almost negligible survival rates 1 that have not improved in decades, despite numerous studies of these tumors in many experimental model systems. Thus there is a need for new experimental model systems in which to study human brain tumors.
Among the currently available models, genetically engineered mouse models (GEMMs) are broadly used for both biological and preclinical investigations. GEMMs relatively accurately mimic the pathophysiological features of human brain tumors, but their application is limited by the genetic, morphological, and physiological differences between human and rodent brains 2 . GEMMs are also relatively expensive and time consuming to establish, which makes them suboptimal as a screening system for tumorigenic drivers from among the numerous candidates identified by brain cancer sequencing projects [3] [4] [5] . Patient-derived xenografts represent, to a large extent, the heterogeneity of human brain tumors, but they are not suitable for studies of tumor initiation. Furthermore, xenografts derived from biopsies take time to establish, and their use is financially infeasible for drug testing 6 . 2D cultures of human brain cancer cell lines and cancer stem cells have served as surrogate models for brain tumors but do not recapitulate the 3D tumor environment 7, 8 . Tumor sphere models generated from either tumor cell lines or cancer stem cells mimic a 3D structure but lack organ-like histology and the interaction between tumor and normal tissues 9, 10 .
The recent development of in vitro organoid culture has opened new avenues for disease modeling directly in human tissues. By recapitulating either organ regeneration from adult stem cells 11 or organ development from pluripotent stem cells 12 , organoids can accurately represent organ histology and physiology 13, 14 . Organoids have been used to model various human diseases 15 , including cancer 16 . Human cerebral organoids recapitulate human brain development in vitro, and have been used to model human neurodevelopmental disorders [17] [18] [19] [20] . Thus far, no in vitro 3D organoid models have been developed that could be used to study human brain tumor initiation, progression, and treatment.
Here we report the development of 3D organoid models for the study of human brain tumor initiation, progression, and response to perturbation. We applied genome-editing techniques to introduce tumorigenic mutations into human cerebral organoids. These models allowed us to test the tumorigenic capability of gain-and lossof-function mutations, singly or in combination, in a systematic manner. We show that mutations found in cancer patients resulted, in our model system, in xeno-transplantable tumors that could be classified as CNS-PNET or glioblastoma (GBM). The neoCOR model is a valuable tool that can be used to study fundamental brain tumor biology and test potential drugs in a personalized setting.
Results
Clonal mutagenesis in cerebral organoids induces tumor overgrowth. A recent reclassification of brain cancer subtypes includes DNA aberrations as a defining feature 21 , highlighting the need for genetically defined human brain cancer models. Brain tumors are characterized by a variety of DNA aberrations that cause oncogene overexpression and/or loss of tumor-suppressor gene function [3] [4] [5] .
To recapitulate tumorigenic events in cerebral organoids, we combined Sleeping Beauty (SB) transposon-mediated gene insertion for oncogene amplification with CRISPR-Cas9-based mutagenesis of tumor-suppressor genes. We introduced combinations of plasmids into cerebral organoids by electroporation before embedding the organoids in Matrigel ( Supplementary Fig. 1a ). The plasmids used encode (1) the SB transposase for integration of inverted repeat (IR)-flanked expression elements into the genome, (2) GFP flanked by SB IRs for cell tracing, (3) any oncogene flanked by IRs for oncogene overexpression, and (4) plasmids expressing the Cas9 nuclease together with guide RNAs for mutagenesis of tumor-suppressor genes in cerebral organoids. This strategy gave us the flexibility to introduce any combination of gain-and/or loss-of-function tumorigenic genes.
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At the end of the neural induction stage of our cerebralorganoid-development protocol 17 (Fig. 1a ), neural stem and progenitor cells (NS/PCs), which are believed to be cells of origin for many different brain tumor subtypes [22] [23] [24] [25] [26] [27] [28] [29] , are expanding on the surface of embryoid bodies (EBs). Immunostaining of both sectioned EBs and adherent cultured EBs 1 d after nucleofection of pCAG-GFP showed that 100% of GFP + cells were SOX1 + , CDH2 + (N-cadherin + ), and NES + NS/PCs (Fig. 1b) . None of the GFP + cells were brachyury + (BRA + ) or FOXF1 + mesodermal cells, or SOX17 + or PECAM1 + (CD31 + ) endodermal cells ( Fig. 1b and Supplementary Fig. 1b-d) . Thus, the electroporated plasmids were delivered exclusively into NS/PCs. We tested whether tumorous overgrowth can be induced in cerebral organoids. We introduced into the organoids 18 single gene mutations or amplifications, as well as 15 of the most common clinically relevant combinations observed in brain tumors such as GBM 3 , pediatric CNS-PNET 30 , atypical teratoid/rhabdoid tumor 31 , and medulloblastoma 5 (Supplementary Table 1 ). As most electroporated cells carried the CAG-GFP insertion, we used GFP intensity to quantify the proliferation of cells carrying gene aberrations. One day after electroporation, EBs from all groups contained similar amounts of GFP + cells ( Fig. 2a,b ). One month later, however, we observed striking overgrowth of GFP + cells in organoids carrying the MYC amplification (MYC OE , where OE indicates overexpression) and in organoids with CDKN2A -/-
and EGFRvIII OE /CDKN2A -/-/PTEN -/genotypes ( Fig. 2a ,c), where EGFRvIII denotes epidermal growth factor receptor variant III, a deletion variant of EGFR1/ERBB1/HER1. As these combinations of gene aberrations are commonly found in GBM, we refer to them as GBM-1, GBM-2, and GBM-3, respectively.
To confirm that the genome-editing techniques actually altered the genome in tumor cells, we analyzed the expression of oncogenes and/or sequencing CRISPR-targeting regions. We observed that tumor cells carried the expected gene mutations/amplifications ( Supplementary Fig. 2a-d ). Thus, cerebral organoids can be used as a platform to test the tumorigenic capacity of different gene aberrations.
MYC OE and GBM-like neoCORs have distinct transcriptional profiles.
To test whether brain-tumor-like organoids resemble distinct brain tumor subtypes, we carried out transcriptome analysis of GFP + cells isolated by FACS. Principal component analysis of the top 500 variable genes between different groups identified three distinct clusters. Cluster 1 included all control (CTRL) organoids, which harbored only CAG-GFP and a control guide RNA targeting dTomato ( Fig. 3a ). Cluster 2 included the organoids carrying the MYC OE construct, and cluster 3 contained the organoids carrying genetic aberrations found in GBM (GBM-1, GBM-2, and GBM-3). On the basis of these clusters, we identified genes that were differentially expressed (DESeq, adjusted P value < 0.05) between cluster 2 or cluster 3 
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hypergeometric test showed that the majority of genes that were deregulated in the MYC OE group (cluster 2) were distinct from those deregulated in the GBM groups (cluster 3) ( Supplementary   Fig. 3a ). Further KEGG pathway analysis of genes with differential expression (DESeq, adjusted P value < 0.05) between cluster 2 and cluster 3 indicated upregulation of metabolic pathway and Average GFP intensity Organoids from four groups showed significant overgrowth at 1 month: MYC OE (n = 7; adjusted P < 0.0001 versus CTRL(SB)), CDKN2A -/-/CDKN2B -/-/EGFR OE /EGFRvIII OE (n = 5; adjusted P < 0.0001 versus CTRL(dT + SB)), NF1 -/-/PTEN -/-/p53 -/-(n = 9; adjusted P < 0.0001 versus CTRL(dT + SB)), and EGFRvIII/PTEN -/-/CDKN2A -/-(n = 6; adjusted P < 0.0001 versus CTRL(dT + SB)). This experiment was performed once. 
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cell-cycle genes in the tumor cells from cluster 2 neoCORs, as well as the Hippo, WNT, TGFβ , and TP53 signaling pathways, which are known to be connected to MYC [32] [33] [34] ( Supplementary  Fig. 3b ). In addition, the MYC OE group showed upregulation of an epithelial differentiation signature, suggestive of a CNS-PNETlike neoplasm of neuroepithelial cellular origin. KEGG pathway analysis also confirmed a glioma signature in cluster 3 neoCORs, and showed upregulation of the PI3K-AKT, RAP1, ERBB, HIF1A, NF-κ B, and estrogen signaling pathways, relevant for GBM [35] [36] [37] [38] [39] ( Supplementary Fig. 3b ).
To test the similarity between the tumor cells from neoCORs and primary tumors, we examined the transcriptome data from neoCORs for genes known to be differentially expressed between CNS-PNET and GBM tumors 30 . Hierarchical clustering revealed that neoCORs from the MYC OE group showed a strong CNS-PNET signature, whereas organoids from cluster 3 showed upregulation of GBM genes (Fig. 3b ). These data suggest that we developed two distinct types of tumor overgrowth in human cerebral organoids, depending on the genetic aberrations induced: CNS-PNET-like and GBM-like neoplastic growths.
MYC OE and GBM-like neoCORs have different cellular identities. In humans, CNS-PNETs are embryonic neuroepithelial neoplasms characterized by sheets of primitive neuroepithelial cells and frequent rosette formations 40 . These undifferentiated cells feature SOX2 expression and high CD99 expression 41 . GBMs, in contrast, are high-grade astrocytic neoplasms with a more diverse morphology featuring glial cell predominance. The glial markers GFAP and S100β , as well as the proliferative marker Ki67, are diagnostic for GBM.
We analyzed the expression of CNS-PNET and GBM markers in MYC OE and GBM neoCORs 4 months after nucleofection. In CTRL organoids, most GFP + cells were HuC/D + neurons (Fig. 3c,d and Supplementary Fig. 4a ), whereas only a small portion of GFP + cells were positive for SOX2 ( Fig. 3c,e and Supplementary Fig. 4b ) and Ki67 (Fig. 3c,f and Supplementary Fig. 4c ) or the glial markers S100β (Fig. 3c,g and Supplementary Fig. 4d ) and GFAP (Fig. 3c,h and Supplementary Fig. 4e ). GFP + cells located in the ventricular zone of cortical regions expressed SOX2 and Ki67, whereas GFP + HuC/D + neurons were located in the basal cortical regions ( Fig. 3c and Supplementary Fig. 4a-f ). 
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In contrast, the MYC OE organoids contained few GFP + cells that were HuC/D + (Fig. 3c,d and Supplementary Fig. 4a ) or that expressed the glial marker S100β (Fig. 3c,g and Supplementary  Fig. 4d ) or GFAP (Fig. 3c,h and Supplementary Fig. 4e ). Instead, most GFP + cells were SOX2 + (Fig. 3c,e and Supplementary Fig. 4b ), and nearly 50% expressed Ki67 (Fig. 3c,f and Supplementary  Fig. 4c ). In addition, most GFP + MYC OE cells expressed high levels of CD99 antigen (Fig. 3c ,i and Supplementary Fig. 4f ), which further confirmed their CNS-PNET-like cellular identities. GFP + cells formed large sheets of cells and rosette structures ( Fig. 3c and Supplementary Fig. 4a-f ).
In the GBM-like groups, GFP + regions were positive for S100β ( Fig. 3c,g, and Supplementary Figs. 4d and 5 ) and GFAP (Fig. 3c,h and Supplementary Figs. 4e and 5 ), indicating their glial identity, and contained only a few HuC/D + neurons (Fig. 3c,d, and Supplementary Figs. 4a and 5 ). Compared with CTRL organoids, they also contained more SOX2 + (Fig. 3c,e and Supplementary  Figs. 4b and 5 ) and Ki67 + (Fig. 3c,f and Supplementary Figs. 4c and 5 ) cells, which are often observed in the central core of GBM tumors 42 . In addition, GFP + regions in GBM-relevant groups showed elevated CD99 levels compared with those in CTRL samples (Fig. 3c,i and Supplementary Figs. 4f and 5 ), a feature also reported for GBM tissues 43 . Tumor regions in the GBM-like organoids showed a disorganized architecture ( Fig. 3c and Supplementary Figs . 4a-f and 5).
We also examined 1-month-old CTRL organoids and neoCORs, which had cellular identities and histological features similar to those of 4-month-old organoids ( Supplementary Figs. 6a-e and 7a-e ). Thus, neoCORs induced by distinct genetic aberrations recapitulate the cellular identities and partial histomorphological features of CNS-PNET or GBM tumors.
NeoCORs retain viability and expand after renal subcapsular engrafting. A capacity for self-renewal and immortality are two hallmarks of cancer cells. To examine whether neo-CORs exhibited these features in vivo, we implanted them into the renal subcapsular space in immunodeficient mice ( Supplementary Fig. 8a ). Four out of five control organoids were resorbed within 6 weeks, and the remaining organoid was reduced to only a tiny cluster of cells ( Fig. 4a) with diminished cellularity and architectural detail (Fig. 4b) .
In contrast, 17 out of 20 neoCORs were retained, and several expanded beyond the renal capsule by the end of the experimental period ( Fig. 4a and Supplementary Fig. 8b ). Immunohistochemical analysis revealed many neuroepithelial areas in organoids of the MYC OE group positive for the NS/PC marker SOX1 (Fig. 4c ) and cell-cycle marker Ki67 (Fig. 4d ), but very few cells positive for the glial marker GFAP (Fig. 4e ) or the neuronal marker MAP2 ( Supplementary Fig. 8c ), indicating their primitive, poorly differentiated state. Transplanted organoids from the MYC OE group proliferated massively ( Fig. 4a and Supplementary Fig. 8b ). They formed cell sheets and rosettes, similar to CNS-PNET ( Fig. 4b and Supplementary Fig. 8d-f ). GBM groups instead showed high expression of the glial marker GFAP, NS/PC marker SOX1, and Ki67 ( Fig. 4c-e ). GBM-1 and GBM-3 organoids displayed a glial neoplasm-like expansion (Fig. 4b) , whereas GBM-2 organoids showed glial neoplasm-like proliferation with additional cells of mature neuronal appearance reminiscent of glioneuronal tumors (Fig. 4b) . Thus, neoCORs can engraft and expand in vivo and maintain their subtype identity after renal transplantation into nude mice.
Use of GBM-like neoCORs to study interactions between tumor and normal tissue.
Compared with other in vitro brain tumor models, a distinct feature of the neoCOR model is that tumors are initiated by the introduction of genetic aberrations into a very small portion of cells in the cerebral organoid. This not only mimics in TGFβ  TGFβ1|1  STAT3  SNAI1  SNAI2  ZEB1  ZEB2  PTPN1  CXCR4  ITGA5  PLAU  CTSB  ADAM10  ADAM17  MMP2  MMP14  TIMP2  TIMP3  CLDN1  CLDN2 CLDN3 OCLN 
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vivo human tumor initiation, but also results in a mixed structure that contains both tumor and normal tissues. This allowed us to use neoCORs to study important properties such as invasiveness.
GBMs are known to display extensive infiltration of adjacent brain parenchyma, accompanied by an epithelial-mesenchymal transition that confers invasive capabilities to tumor cells 44, 45 . To assess whether neoCORs can be used to study this process, we evaluated the interface between tumor and normal cells in GBM-like neo-CORs. We observed GFP + tumor cells in normal regions (Fig. 5a-c) . We also observed small foci of tumor cells that breached the renal capsule in the renal xenografts of GBM-group neoCORs (Fig. 5d) .
We compared the expression levels of invasion-related genes in tumor cells from 4-month-old neoCORs of all three GBM groups and normal cells from same-age CTRL organoids, using RNA-seq analysis of FACS-sorted cells. Hierarchical clustering of samples based on reported GBM invasiveness-relevant genes 46 , including genes that encode transcription factors related to epithelial-mesenchymal transition (TGFB, TGFB1I1, STAT3, SNAI2, ZEB1, ZEB2), migration-related receptor (CXCR4), extracellular matrix molecules (ITGA5), and proteases (PLAU, CTSB, ADAM10, ADAM17, MMP2, MMP14), showed that tumor cells from all GBM neoCORs clustered together and had higher expression levels of invasivenessrelevant genes compared with those in normal cells from CTRL organoids and tumor cells from the MYC OE group (Fig. 5e ). In addition, tumor cells from all GBM groups exhibited downregulation of many genes involved in the inhibition of tumor invasion compared with expression in normal cells in CTRL organoids, such as genes encoding tissue inhibitors of matrix metalloproteinases (TIMP2, TIMP3) and tight junction components (CLDN1, CLDN2, CLDN3, OCLN) 46 (Fig. 5e ). We further clustered tumor cells from different GBM groups into individual groups on the basis of expression levels of various invasiveness-related genes. Most invasion-related genes were downregulated in MYC OE neoCORs compared with their expression in the GBM groups (Fig. 5e ), which correlates with the lower infiltration tendency of embryonic neoplasms compared with that of astrocytic neoplasms 40 .
Immunostaining of organoids for the mesenchymal marker vimentin (VIM), urokinase (PLAU), and matrix metalloproteinase 2 (MMP2) confirmed that tumor cells in GBM neoCORs expressed these invasiveness genes at higher levels compared with those in the surrounding normal tissues (Fig. 5f ).
NeoCORs are suitable for targeted drug testing. Because our approach initiates tumorigenesis by introducing defined gene aberrations, the neoCORs could potentially be used for targeted drug testing. To examine this, we assessed the effect of the EGFR inhibitor afatinib, currently in a clinical trial for GBM (NCT number NCT02423525), as a proof of principle (Fig. 6a ). Forty days after treatment, afatinib-treated samples showed significantly reduced ratios of tumor cells in GBM-1 (P = 0.0005) and GBM-3 (P = 0.0004) organoids compared with those in DMSO-treated neoCORs from the same groups (Fig. 6b,c) , but no effect in the MYC OE and GBM-2 groups (Fig. 6d,e) , consistent with the fact that only GBM-1 and GBM-3 organoids show EGFR overactivation. Thus, neoCORs can be used to test the effect of chemical compounds on tumors that originate from specific driver mutations.
In an effort to adapt this method for large-scale screening, we modified the neoCOR system to include firefly luciferase to enable measurement of tumor size ( Supplementary Fig. 9a ). We applied five different EGFR inhibitors-afatinib, erlotinib, and gefitinib, which are approved for different types of cancers, and the experimental drugs canertibib and pelitinib-to GBM-1 organoids. Forty days after drug treatment, organoids treated with afatinib (P = 0.0076) and erlotinib (P = 0.0074) showed significantly reduced firefly luciferase activity in comparison with DMSO-treated neoCORs ( Supplementary Fig. 9b ). Thus, these results suggest that our model could be used to identify the efficacy of different compounds in the context of drug screening.
discussion
By recapitulating genetic aberrations found in people with brain cancer via genome-editing techniques in cerebral organoids, we have generated a new in vitro model system for human brain tumors, which we have named neoCORs. These models exhibit many features of cancer, such as cellular identities, cancer-pathway-specific transcriptome profiles, and the capacity for in vivo expansion and invasion. We identified three combinations of 
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mutations that induce glial-orientated differentiation and abnormal overgrowth, indicating their glial neoplasm-like identities. By overexpressing the oncogene MYC, we were able to generate neoCORs with histopathological features, cellular identities, and transcriptome signatures very similar to those described for human CNS-PNET 30, 40 , a tumor for which no successful animal or in vitro model exists 47 . It is interesting to note that the amplification of MYC alone was sufficient to initiate CNS-PNET-like neoplasm in cerebral organoids within a very short period of time, whereas in animal models, normally additional genetic events such as the loss of p53 and much longer experimental times are required, with low incidence 27 . Unlike previous 3D culture models, such as brain tumor spheres 9, 48 , neoCORs allow the functional analysis of genome aberrations within the same genetic background. In organoids started from patient-derived induced pluripotent stem cells, neoCORs could be further used to test the susceptibility of individuals to different combinations of driver mutations.
In contrast to brain tumor spheres and 2D glioblastoma cell cultures, neoCORs mimic in vivo structural organization, to a certain degree. They contain both tumor cells and normal cells within the same culture, so that interactions between transformed and nontransformed cells can be analyzed. This feature of neoCORs makes them not only very useful for studies of essential tumor biology, but also valuable for preclinical investigation. For drug screening, this particular situation allows for an analysis of antitumor effects accompanied by a safety test in the same system. Like most organoid systems, neoCORs are limited by their lack of vasculature, and therefore certain features of GBM such as glomeruloid microvascular proliferations and perivascular palisading necrosis are not observable. Coculture organoid systems like the ones generated for microglia 49 and/or endothelial cells 50 might help scientists overcome these limitations in the future.
Taken together, our results demonstrate the power of the neo-COR model system to further knowledge of human brain tumor biology by enabling screening of tumorigenic drivers. The system will complement other models and clinical studies designed to investigate molecular mechanisms of tumor initiation, invasion, and progression. It also opens the doors to validation of potential pharmacologic and biologic therapeutic approaches and exploratory drug discovery.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41592-018-0070-7.
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The unstranded reads were screened for ribosomal RNA by alignment with BWA (v0.7.12) against known rRNA sequences (RefSeq). The rRNA subtracted reads were aligned with TopHat (v2.1.1) against the Homo sapiens genome (hg38). Microexon search was enabled. Additionally, a gene model was provided as GTF (UCSC, 2015_01, hg38). rRNA loci were masked on the genome for downstream analysis. Aligned reads were subjected to TPM estimation with Kallisto (v0.43.0). Furthermore, the aligned reads were counted with HTSeq (v0.6.1; intersectionnonempty) and the genes were subjected to differential expression analysis with DESeq2 (v1. 12.4) .
Before the bioinformatics analysis, the expression of oncogenes according to the genome-editing manipulation was checked, and one 4-month-old sample from the GBM-3 neoCOR group was excluded from further analysis because of the failure to introduce overexpression of EGFRvIII.
Principal component analysis was carried out with the top 500 variable genes between normal cells from CTRL organoids and tumor cells from different neoCOR groups. A Venn diagram hypergeometric test was conducted on genes with differential expression between cluster 2 or cluster 3 and the CTRL, and KEGG pathway enrichment analysis was carried out on genes with differential expression between cluster 2 and cluster 3 with an adjusted absolute log 2 (fold change (FC)) value > 0.5 and adjusted P value < 0.05. A Venn diagram hypergeometric test was performed in R language. KEGG pathway enrichment was analyzed with DAVID Bioinformatics (https://david.ncifcrf.gov) 56 . The heat map of RNA-seq data was generated with MeV 57 . For the heat map of tumor-type gene profiling (Fig. 3c) , genes that were differentially expressed between cluster 2 and cluster 3 (adjusted absolute log 2 FC value > 1 or < -1 and adjusted P value < 0.05) were selected from the list of differentially expressed genes (adjusted absolute log 2 FC value > 1 or < -1 and adjusted P value < 0.05) from human primary tumor transcriptome analysis 30 . For the heat map of hierarchical clustering analysis of GBM invasiveness-relevant genes (Fig. 5e ), we selected genes from any individual GBM groups with differential expression relative to that in CTRL organoids with an adjusted absolute log 2 FC value > 0.5 and adjusted P value < 0.05. The heat map was created from log 2 (TPM) transformed data that were row (gene) normalized using the "Median Center Genes/Rows" and "Normalize Genes/Rows" functions to report data as relative expression between samples.
Verification of genome alteration introduced by SB and CRISPR-Cas9.
To test whether the genome-editing techniques actually altered the genome in tumor cells, we used FACS to sort GFP + tumor cells for genomic DNA isolation for genotyping and for RNAs to verify the expression of oncogenes. RNAs were isolated with the RNeasy micro kit (Qiagen), and cDNA was synthesized according to a previously described method 58 . RT-PCR for MYC, EGFR/EGFRvIII, and TBP was done with the primers listed in Supplementary Table 4 . Genomic DNAs were isolated with DNeasy Blood & Tissue kits (Qiagen) according to the manufacturer's instruction. The CRISPR-Cas9-targeted genome loci of tumor-suppressor genes were amplified using the primers listed in Supplementary Table 5 . The PCR products were inserted into T vector (Promega) according to the manufacturer's instructions. Ninety-six colonies per gene were cultured for sequencing.
Renal subcapsular engrafting. All procedures were performed in accordance with institutional animal care guidelines and ethical license protocols. Briefly, adult MF1 nu/nu male mice (8-12 weeks old) were anesthetized with ketamine solution. After disinfection of the surgical site with 70% alcohol, a 1.5-to 2-cm incision was made and the kidney was carefully exteriorized. A 2-to 4-mm incision was made in the renal capsule with a pipette tip, and a capsule pocket for the grafts was made with a blunted glass Pasteur pipette. Two-month-old organoids from each group were carefully implanted under renal capsules (one organoid per capsule). Then the kidney was gently replaced in the retroperitoneal cavity. During the exteriorization, the kidney was kept hydrated by application of PBS with penicillin-streptomycin. The kidneys were collected 1 week and 1.5 months after xenograft for further analysis. The experiments were performed three times independently with different numbers of mice/grafts. In total, at least three engrafted organoids per group were analyzed.
Immunofluorescence and immunohistochemistry. For immunofluorescence staining, tissues were fixed in 4% paraformaldehyde (PFA) at 4 °C overnight. The tissues were dehydrated in 30% sucrose overnight, embedded in Tissue-Tek (VWR), and then cryosectioned at 16 μ m. Sections were blocked and permeabilized in 0.5% Triton X-100 and 4% normal donkey serum (NDS) in PBS at room temperature (RT). Sections were incubated at 4 °C with primary antibody in 0.1% Triton X-100 and 4% NDS in PBS. After being washed three times for 10 min with PBS, sections were incubated with secondary antibodies in 0.1% Triton X-100 and 4% NDS in PBS and DAPI consecutively for visualization of the immunostains. For immunofluorescence staining of adherent cell culture, cells on a coverslip were fixed in 4% PFA for 30 min, blocked and permeabilized in 0.5% Triton X-100 and 4% NDS in PBS at RT for 30 min, and incubated with primary and secondary antibodies for 1 h at RT sequentially. Then the cells were incubated with DAPI for nuclei staining and mounted with DAKO fluorescence mounting medium. The primary and secondary antibodies used for immunofluorescence are listed in Supplementary Tables 6 and 7 . Images were captured with a confocal Methods microscope (Zeiss LSM 780) and a fluorescence microscope (Zeiss Axio Imager 2). Quantification of images from three independent preparations of neoCORs was done in Fiji. The experiments were performed on samples from three independent preparations.
For histologic and immunohistochemical staining, tissues were fixed in 4% paraformaldehyde overnight. Fixed tissues were rinsed in PBS, dehydrated by immersion in an ascending ethanol gradient (70%, 90%, and 100% ethanol), embedded in paraffin, and sectioned at a thickness of 2-5 μ m. Sections were stained via a routine hematoxylin and eosin (H&E) protocol in a Microm HMS 740 automated stainer. Immunohistochemistry was performed with the Leica Bond III automated immunostainer. The primary and secondary antibodies used in this study are listed in Supplementary Tables 6 and 7 . Slides were reviewed with a Zeiss Axioskop 2 MOT microscope, and images were acquired with a SPOT Insight digital camera. Slides were also scanned with a Pannoramic 250 Flash II scanner (3D Histech). Digital slides were reviewed and images acquired with the Pannoramic Viewer software (3D Histech). Slides were reviewed by a boardcertified veterinary comparative pathologist (A.K.).
For quantification of immunofluorescence staining, images from at least three organoids per group, collected from three independent experiments, were analyzed. Detailed sample sizes are stated in the relevant figure legends and the associated source data (available online).
Drug testing on neoplastic cerebral organoids. For drug testing, neoCORs were first grown for 2 months and then subjected to drug treatment for 40 d. EGFR inhibitors afatinib (http://www.selleckchem.com; cat. no. S1011), erlotinib (http:// www.selleckchem.com; cat. no. S7786), gefitinib (http://www.selleckchem.com; cat. no. S1025), canertinib (http://www.selleckchem.com; cat. no. S1019), and pelitinib (Sigma-Aldrich; cat. no. 257933-82-7) (final concentration: 1 μ M) were applied, and DMSO was used as the control. After drug treatment, neoCORs were trypsinized for single-cell preparation and then subjected to FACS analysis. We counted total cell numbers to evaluate the cytotoxicity of the drugs. The drugtesting experiments were performed twice independently.
Flow cytometry. Flow cytometry experiments differed according to the different experimental purposes. For RNA-seq analysis, organoids were trypsinized to make single-cell suspensions. GFP + cells were collected with a BD FACSAria III. Live cells were gated to sort GFP + cells for further RNA-seq analysis. For drug-testing experiments, organoids were trypsinized to make single-cell suspensions. The proportion of GFP + cells was analyzed with a BD LSR Fortessa 2. Live cells were gated for analysis of the GFP + cell proportion. All cells were analyzed for GFP + cell proportion. Data were analyzed with BD FACSDiva software. An example representing the gating strategy is presented in Supplementary Fig. 10 . A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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